Clovis Oncology has come out of the gate at ASCO with updated–and promising–data on its targeted lung cancer drug CO-1686, offering fresh evidence of its durability and effectiveness.

…read more

Source: Clovis Oncology preps for a blockbuster showdown with AstraZeneca